A group of individual investors has acquired Saneca/Slovakofarma Hlohovec
In this asset deal, a group of private investors has acquired Saneca's cosmetic products portfolio and its pharmaceutical manufacturing plant in Slovakia, from Sanofi. Financial terms of this transaction have not been disclosed.
Saneca (originally Zentiva Hlohovec) is a pharmaceutical contract manufacturing company active in the development, production, registration and distribution of generic medicines and active pharmaceutical ingredients. Saneca also owns portfolio of cosmetic and generic products.
Sanofi is a global integrated healthcare leader engaged in the research, development, manufacturing and marketing of therapeutic solutions.
Oaklins' team in Slovakia advised the buyer in this transaction. The process included due diligence, valuation, negotiation of transaction terms, and selection of new management in the newly purchased entity.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more